ACC 22: Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events

Подробнее о видео

Watch the full video on Radcliffe Cardiology here:

Dr Paul Ridker (Brigham and Women’s Hospital, Boston, US) outlines the findings from a secondary analysis of the CANTOS trial, originally presented at ACC 2022 (NCT01327846). CANTOS was a large multinational clinical trial that showed targeting inflammation with canakinumab significantly lowered major cardiovascular events. This secondary analysis was designed to evaluate the influence of lipids and inflammation on atherosclerotic events.

Discussion Points:
1. Outcomes of the CANTOS Study and the Importance of this Sub-study
2. Study Design
3. Key Findings
4. Influence on Scientific Research
5. Interpreting the Results from a Clinical Perspective
6. Take-home Messages

Recorded remotely from Boston, 2022.
Interviewer: Jordan Rance

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.